Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $12.67

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have received a consensus rating of “Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $13.25.

A number of brokerages recently issued reports on GOVX. Alliance Global Partners initiated coverage on GeoVax Labs in a report on Monday. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Finally, Noble Financial boosted their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $2.70 on Monday. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18. The company’s 50 day moving average is $2.44 and its two-hundred day moving average is $2.59.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the company earned ($4.80) EPS. As a group, research analysts forecast that GeoVax Labs will post -5.1 earnings per share for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.